Trial Profile
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs Tesevatinib (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Kadmon Corporation
- 01 Oct 2020 According to a Biocept media release, results from this trial will be discussed in a poster presentation at the International Association for the Study of Lung Cancer (IASLC) Virtual Lung Cancer Hot Topic Meeting: Liquid Biopsy.
- 18 Jan 2019 Status changed from active, no longer recruiting to completed.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer